Know Cancer

or
forgot password

Gene Expression Profiling of Infant Embryonal Central Nervous System Tumors by Microarray Gene Chip Analysis: Angiogenesis, Invasion and Metastasis


N/A
N/A
2 Years
Not Enrolling
Both
Central Nervous System Embryonal Neoplasm

Thank you

Trial Information

Gene Expression Profiling of Infant Embryonal Central Nervous System Tumors by Microarray Gene Chip Analysis: Angiogenesis, Invasion and Metastasis


OBJECTIVES:

- Identify known genes that have significantly different levels of expression, using
microarray gene chip analysis, in infants with newly diagnosed metastatic vs
non-metastatic embryonal central nervous system tumors.

- Determine the protein expression of genes identified by microarray analysis that are
involved in cellular functions that regulate angiogenesis, invasion, or metastasis in
this patient population.

- Determine the quantity of gene expression of the confirmed translationally expressed
genes using semi-quantitative polymerase chain reaction.

OUTLINE: This is a multicenter study.

Tumor samples are analyzed using microarray gene chip analysis. Differentially expressed
genes are evaluated for protein expression by standard immunohistochemistry and/or Western
blot analysis, and gene expression is further quantified by semi-quantitative polymerase
chain reaction.

PROJECTED ACCRUAL: Approximately 80-100 patients (20-25 with metastatic disease and 60-75
with non-metastatic disease) will be accrued for this study within 4-5 years.

Inclusion Criteria


DISEASE CHARACTERISTICS:

- Histologically confirmed, newly diagnosed, primary intracranial embryonal central
nervous system tumor

- Medulloblastoma

- Primitive neuroectodermal tumor

- Medulloepithelioma

- Ependymoblastoma

- Neuroblastoma

- Pineoblastoma

- Atypical teratoid/rhabdoid tumor

- Intracranial germ cell tumor

- Choroid plexus carcinoma

- M positive ependymoma

- Potential enrollment on PBTC-001 therapeutic protocol

PATIENT CHARACTERISTICS:

Age:

- Under 3

Performance status:

- Not specified

Life expectancy:

- Not specified

Hematopoietic:

- Not specified

Hepatic:

- Not specified

Renal:

- Not specified

PRIOR CONCURRENT THERAPY:

Biologic therapy:

- Not specified

Chemotherapy:

- No prior chemotherapy

Endocrine therapy:

- Prior steroids allowed

Radiotherapy:

- No prior radiotherapy

Surgery:

- Not specified

Other:

- No concurrent investigational agents

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

Genes that are expressed in metastatic vs. non-metastatic tumors

Outcome Time Frame:

Prior to therapy

Safety Issue:

No

Principal Investigator

Tobey MacDonald, MD

Investigator Role:

Study Chair

Investigator Affiliation:

Children's Research Institute

Authority:

United States: Federal Government

Study ID:

CDR0000068446

NCT ID:

NCT00010114

Start Date:

March 2001

Completion Date:

March 2003

Related Keywords:

  • Central Nervous System Embryonal Neoplasm
  • childhood central nervous system germ cell tumor
  • childhood choroid plexus tumor
  • untreated childhood supratentorial primitive neuroectodermal tumor
  • untreated childhood medulloblastoma
  • newly diagnosed childhood ependymoma
  • Neoplasms
  • Neoplasms, Germ Cell and Embryonal
  • Nervous System Neoplasms
  • Central Nervous System Neoplasms

Name

Location

Baylor College of MedicineHouston, Texas  77030
Children's Hospital of PhiladelphiaPhiladelphia, Pennsylvania  19104
Duke Comprehensive Cancer CenterDurham, North Carolina  27710
UCSF Cancer Center and Cancer Research InstituteSan Francisco, California  94115-0128
Dana-Farber Cancer InstituteBoston, Massachusetts  02115
Children's National Medical CenterWashington, District of Columbia  20010-2970
Children's Hospital of PittsburghPittsburgh, Pennsylvania  15213
Children's Hospital and Regional Medical Center - SeattleSeattle, Washington  98105
Saint Jude Children's Research HospitalMemphis, Tennessee  38105-2794